31804-36-1

Basic information

• Product Name: 1-BROMO-3-METHOXY-2-METHYLBENZENE
• Synonyms: 1-BROMO-3-METHOXY-2-METHYLBENZENE;3-Bromo-2-methylanisole
• CAS NO: 31804-36-1
• Molecular Formula: C₈H₉BrO
• Molecular Weight: 201.07
• Mol File: 31804-36-1.mol

Chemical Properties

• Melting Point: 150-151 °C
• Boiling Point: 217°C at 760 mmHg
• Flash Point: 99.3°C
• Appearance: /
• Density: 1.378g/cm³
• Vapor Pressure: 0.199mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-BROMO-3-METHOXY-2-METHYLBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-3-METHOXY-2-METHYLBENZENE(31804-36-1)
• EPA Substance Registry System: 1-BROMO-3-METHOXY-2-METHYLBENZENE(31804-36-1)

Safety Data

• Hazardous Substances Data: 31804-36-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-Bromo-3-methoxy-2-methylbenzene is used as a reagent in laboratory settings for organic synthesis, particularly in the preparation of various organic compounds.
Used in Pharmaceutical Industry:
1-Bromo-3-methoxy-2-methylbenzene is used as an intermediate in the manufacturing of pharmaceuticals, contributing to the development of new drugs and medicines.
Used in Dye Manufacturing:
1-BROMO-3-METHOXY-2-METHYLBENZENE is also utilized as a key component in the production of dyes, playing a significant role in the coloration and properties of various dyes used in different industries.
Used in Other Organic Compounds Production:
1-Bromo-3-methoxy-2-methylbenzene serves as a building block in the synthesis of other organic compounds, expanding its applications across various chemical and industrial processes.

InChI:InChI=1/C8H9BrO/c1-6-7(9)4-3-5-8(6)10-2/h3-5H,1-2H3

Upstream product

• 4837-88-1 6-methoxy-2-nitrotoluene 
• 55289-36-6 3-bromo-2-methylaniline 
• 19500-02-8 2-methyl-3-methoxyaniline 
• 7766-23-6 3-bromo-2-methylphenol 
• 77-78-1 dimethyl sulfate 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 74-88-4 methyl iodide 

Downstream Products

• 573693-11-5 2-bromo-4-methoxy-3-methyl-1-nitro-benzene 
• 573693-08-0 2-bromo-4-methoxy-3-methyl-phenylamine 
• 573693-12-6 3-(2-bromo-4-methoxy-3-methyl-phenylamino)-4-methoxy-benzoic acid methyl ester 
• 573693-14-8 8-bromo-1,6-bis-(tert-butyl-diphenyl-silanyloxy)-7-methyl-9H-carbazole-4-carboxylic acid methyl ester 
• 573693-16-0 [1,6-bis-(tert-butyl-diphenyl-silanyloxy)-8-(2,5-dimethyl-hex-1-enyl)-7-methyl-9H-carbazol-4-yl]-methanol 
• 573693-15-9 1,6-bis-(tert-butyl-diphenyl-silanyloxy)-8-(2,5-dimethyl-hex-1-enyl)-7-methyl-9H-carbazole-4-carboxylic acid methyl ester 
• 868694-07-9 5-bromo-2-(3-methoxy-2-methylbenzoyl)-benzoic acid 
• 868694-08-0 4-bromo-2-(3-methoxy-2-methylbenzoyl)-benzoic acid 

Relevant articles and documents

Divergent Enantioselective Synthesis of (Nor)illudalane Sesquiterpenes via Pd0-Catalyzed Asymmetric C(sp3)-H Activation

A divergent enantioselective synthesis of (nor)illudalane sesquiterpenes was designed by using a Pd0-catalyzed asymmetric C(sp3)-H arylation as a key step to control the isolated, highly symmetric quaternary stereocenter of the targe

Total Synthesis of (Nor)illudalane Sesquiterpenes Based on a C(sp3)-H Activation Strategy

Three (nor)illudalane sesquiterpenes were synthesized from a common intermediate in racemic and enantioenriched forms using Pd0-catalyzed C(sp3)-H arylation as a key step. The configuration of the isolated, highly symmetric quaternar

Axially Chiral Dibenzazepinones by a Palladium(0)-Catalyzed Atropo-enantioselective C?H Arylation

Atropo-enantioselective C?H functionalization reactions are largely limited to the dynamic kinetic resolution of biaryl substrates through the introduction of steric bulk proximal to the axis of chirality. Reported herein is a highly atropo-enantioselective palladium(0)-catalyzed methodology that forges the axis of chirality during the C?H functionalization process, enabling the synthesis of axially chiral dibenzazepinones. Computational investigations support experimentally determined racemization barriers, while also indicating C?H functionalization proceeds by an enantio-determining CMD to yield configurationally stable eight-membered palladacycles.

Propionic Acid Derivatives and Methods of Use Thereof

Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5 and Ar are as described herein, compositions including compounds and methods of using the compounds.

NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II

The invention relates novel NK1 receptor antagonists represented in formula A, wherein R1 and R2 independently are selected from the group consisting of (C1-4)alkyl, (C1-4)haloalkyl, (C1-4)alkoxy, CD

NRF2 REGULATORS

The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

DERIVATIVES OF 1-PHENYL-1,5-DIHYDRO-BENZO[B] [1.4]DIAZEPINE-2.4-DIONE AS INHIBITORS OF HIV REPLICATION

Compounds of formula (I) wherein m, R1, R2, R3, X and Y are defined herein, are useful as inhibitors of HIV replication.

Total synthesis of new lipocarbazoles isolated from the actinomycete tsukamurella pseudospumae acta 1857

New lipocarbazoles were synthesized by a sequence of three palladium-mediated coupling reactions and an improved protecting group strategy.

BENZOXAZOCINES AND THEIR THERAPEUTIC USE AS MONOAMINE REUPTAKE INHIBITORS

Compounds having therapeutic utility are of general formula (1) wherein R, is H, C 1-C6 alkyl optionally substituted with F or C3-C6 cycloalkyl or C2-C4 alkenyl; A is O, CH2 or S(O)n where n is 0-2; one of W, X, Y and Z is N, CH or CR3 and the others are CH; R2 is C5-C6 heteroaryl, C5-C10 cycloalkyl or cycloalkenyl optionally containing one or more heteroatoms selected from O, N and S(O)n where n is 0-2, and optionally substituted with R3; or a phenyl group optionally substituted in one or more positions with one or more substituents independently selected from halogen, CN, CF3, C1-C6 alkyl and OR1, or the phenyl group is fused to a five or six membered ring which may be carbocyclic, heterocyclic (containing 1-2 heteroatoms selected from O, N and S), aromatic or heteroaromatic (containing 1-2 heteroatoms selected from O and N); R3 is selected from halogen; CF3; CN; OR5; SO2N(R5)2; COR5; CO2R5; CON(R5)2; NR1,COR4; NR1SO2R4; NR1CO2R4; NR1,CON(R5)2; OC1-C6 alkyl substituted with R3; C1-C6 alkyl optionally substituted with unsubstituted R3; C3-C6 cycloalkyl optionally substituted with unsubstituted R3; C2-Cs alkenyl optionally substituted with unsubstituted R3; C2-Cs alkynyl optionally substituted with unsubstituted R3; aryl optionally substituted with unsubstituted R3; and five or six membered aromatic heterocycles containing 1-4 heteroatoms selected from N and O; R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, aryl and heteroaryl; and R5 is H, C1-C6 alkyl; C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, aryl or heteroaryl and is the same as or different to another R5; or a pharmaceutically acceptable salt thereof.